FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Deutsche Boerse AG 01:10:14 15/06/2024 am IST | ||
| 0.035 EUR | -12.50% |
|
| 1 month | -20.45% | ||
| 3 months | -86.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 0.035 | -12.50% |
| 13/24/13 | 0.04 | +5.26% |
| 12/24/12 | 0.038 | -5.00% |
| 11/24/11 | 0.04 | +17.65% |
| 10/24/10 | 0.034 | -2.86% |
Delayed Quote Deutsche Boerse AG
Last update June 15, 2024 at 01:10 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SH8ETS |
| ISIN | DE000SH8ETS7 |
| Date issued | 06/04/2022 |
| Strike | 10,166 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.93 € |
|---|---|
| Lowest since issue | 0.032 € |
| Spread | 0.01 € |
| Spread % | 22.22% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
174.4
USD
Spread / Average Target
+9.95%
- Stock Market
- Certificates
- Certificat
